JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
1.0
Cite Score 2025
SJR: 0.129 / SNIP: 0.140
Volume 17, Issue 4 (2025)
Iran J War Public Health 2025, 17(4): 399-405 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2025/10/19 | Accepted: 2025/11/25 | Published: 2025/11/30
Received: 2025/10/19 | Accepted: 2025/11/25 | Published: 2025/11/30
How to cite this article
Rasheed Z, Ayyed H, Taha J. Assessment of Minimal Erythema Dose of Narrow Band Ultraviolet-B in a Sample of Iraqi Patients with Vitiligo and Psoriasis. Iran J War Public Health 2025; 17 (4) :399-405
URL: http://ijwph.ir/article-1-1713-en.html
URL: http://ijwph.ir/article-1-1713-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Physics, Faculty of Education, Al-Iraqia University, Baghdad, Iraq
2- Department of Physiology, Faculty of Medicine, Al-Nahrain University, Baghdad, Iraq
2- Department of Physiology, Faculty of Medicine, Al-Nahrain University, Baghdad, Iraq
Abstract (462 Views)
Aims: This study aimed to determine the minimal erythema dose in a group of patients with vitiligo and psoriasis from Iraq.
Materials & Methods: This analytical cross-sectional study was conducted on 21 patients (13 females and 8 males, aged 9 to 60 years) with psoriasis and vitiligo who attended the Department of Dermatology at the Medical City Teaching Hospital, Baghdad, over a four-month period. Fifteen patients had vitiligo, while six had psoriasis. Skin type was III in 10 patients and IV in 11. A complete general, systemic, and dermatological examination was performed, including the number of depigmented macules, the site of involvement, and the approximate percentage of body surface area affected. Data were analyzed using Microsoft Office Excel 2010 with a two-tailed t-test.
Findings: The minimal erythema dose ranged from 350 to 600mJ/cm². The mean minimal erythema dose was 448.1±87.6mJ/cm². There were no statistically significant differences between males (457.50±119.13mJ/cm²) and females (442.30±66.35mJ/cm²; p=0.710). Likewise, no significant difference was observed between patients with psoriasis (430.00±84.61mJ/cm²) and those with vitiligo (455.33±90.5mJ/cm²; p=0.563). In addition, there was no significant difference between patients with skin type III (447.00±89.69mJ/cm²) and skin type IV (449.09±89.93mJ/cm²; p=0.958).
Conclusion: Gender, disease type (vitiligo or psoriasis), and skin types III and IV do not affect the minimal erythema dose.
Materials & Methods: This analytical cross-sectional study was conducted on 21 patients (13 females and 8 males, aged 9 to 60 years) with psoriasis and vitiligo who attended the Department of Dermatology at the Medical City Teaching Hospital, Baghdad, over a four-month period. Fifteen patients had vitiligo, while six had psoriasis. Skin type was III in 10 patients and IV in 11. A complete general, systemic, and dermatological examination was performed, including the number of depigmented macules, the site of involvement, and the approximate percentage of body surface area affected. Data were analyzed using Microsoft Office Excel 2010 with a two-tailed t-test.
Findings: The minimal erythema dose ranged from 350 to 600mJ/cm². The mean minimal erythema dose was 448.1±87.6mJ/cm². There were no statistically significant differences between males (457.50±119.13mJ/cm²) and females (442.30±66.35mJ/cm²; p=0.710). Likewise, no significant difference was observed between patients with psoriasis (430.00±84.61mJ/cm²) and those with vitiligo (455.33±90.5mJ/cm²; p=0.563). In addition, there was no significant difference between patients with skin type III (447.00±89.69mJ/cm²) and skin type IV (449.09±89.93mJ/cm²; p=0.958).
Conclusion: Gender, disease type (vitiligo or psoriasis), and skin types III and IV do not affect the minimal erythema dose.